Earlier vasopressin in septic shock shows observational benefit, but randomized evidence remains lacking

A commentary in Intensive Care Medicine assesses accumulating observational evidence for earlier adjunctive vasopressin in septic shock. It highlights a trial emulation using two large US databases, comparing initiation within 0–3 hours (744 patients) versus >3–6 hours (293 patients) after norepinephrine first reached at least 0.25 mcg/kg/min. Current sepsis guidelines recommend vasopressin for patients not responding to norepinephrine.

Ultra-early initiation was associated with a 5-percentage-point reduction in 28-day mortality compared with the early strategy (95% CI, −6.8 to −3.2 percentage points). Secondary findings included less renal replacement therapy, lower fluid balance and fewer medically treated arrhythmias. No differences were detected in mesenteric or digital ischemia or coagulation disorders. Associations with lower mortality persisted across the reported subgroup analyses.

The commentary emphasizes that timing was measured from a norepinephrine-dose threshold, not shock onset; the time needed to reach that threshold could reflect important clinical differences. Although the analysis used cloning, censoring and weighting to address bias, residual confounding remains possible. Time-varying covariates were included in the censoring model but not in post-treatment outcome adjustment.

No randomized trial has demonstrated that adjunctive vasopressin reduces septic shock mortality. The authors conclude that the observational findings support further investigation, rather than a practice change, pending large multicenter randomized trials establishing efficacy and safety.